Patented Ibuprofen, Famotidine Formulation Is Invalid, Panel Affirms

Mealey's (November 17, 2021, 1:26 PM EST) -- WASHINGTON, D.C. — In a Nov. 16 holding the Federal Circuit U.S. Court of Appeals agreed with a federal judge in Delaware that a generic drug maker was entitled to prevail...
To view the full article, register now.